Nucleic Acids Therapeutics - Making Sense of Antisense

July 28, 2016
Session 7 of the 2016 Drug Design and Delivery Symposium


Drug Design logo with the number 7

Unmodified oligonucleotides are highly charged, polyanionic macromolecules with poor drug-like properties and a lot of potential. Tune in as Punit Seth of Ionis describes the use of chemical modification strategies to enhance the stability, binding affinity, pharmacokinetic and toxicological properties of oligonucleotide drugs.

What You Will Learn

  • General design principles for making an oligonucleotide drug
  • Chemical modification strategies to enhance drug-like properties of oligonucleotide drugs
  • Recent developments in targeted delivery of oligonucleotide therapeutics

The Fine Print

ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.

ACS Webinars logo

Experts

Punit Seth
Ionis Pharmaceuticals

Richard Olson
Bristol-Myers Squibb 

Co-Produced By